Volume : 12, Issue : 10, October – 2025
Title:
DIFFERENTIAL OUTCOMES AND TREATMENT PATTERNS IN ACUTE HEART FAILURE STRATIFIED BY RENAL FUNCTION: A PROSPECTIVE OBSERVATIONAL STUDY
Authors :
Abdul Rahman*Tahoora Tareq
Abstract :
Abstract:
Background & Aim: Heart failure (HF) remains one of the leading causes of morbidity and mortality worldwide, and renal dysfunction is a frequent comorbidity that complicates its management. This study sought to compare clinical features, treatment strategies, and outcomes in patients admitted with acute heart failure (AHF), stratified by renal function.
Methods: In this prospective observational study conducted at a tertiary care hospital in Hyderabad between September 2019 and February 2021, 132 patients with AHF were enrolled. Based on estimated glomerular filtration rate (eGFR), participants were categorized into Group A (eGFR >60 ml/min/1.73 m²; n=50) and Group B (eGFR ≤60 ml/min/1.73 m²; n=82). Clinical parameters, laboratory values, and therapeutic patterns were recorded during hospitalization and outcomes (NYHA class, readmission, mortality) were assessed at 1-year follow-up.
Results: Among the total cohort, 65 patients (49.2%) had HFrEF, 41 (31.0%) had HFmrEF, and 26 (19.6%) had HFpEF. Renal impairment was most prevalent in HFpEF cases (73.1%). Compared with Group A, patients in Group B were less frequently prescribed ACEIs/ARBs (30% vs. 58%; p<0.01) and digoxin (20% vs. 42%; p<0.01), but more often received hydralazine–isosorbide dinitrate (48% vs. 16%; p<0.001). One-year mortality was significantly higher in Group B (38.5% vs. 14.0%; p=0.002). Improvement in NYHA class was lower in Group B (34.1% vs. 48.0%).
Conclusion: Renal impairment in AHF patients was associated with poorer outcomes and underutilization of guideline-directed therapies. eGFR was a stronger predictor of mortality than the left ventricular ejection fraction. Optimizing therapy in patients with co-existing renal dysfunction warrants further clinical investigation
Cite This Article:
Please cite this article in press Abdul Rahman et al., Differential Outcomes And Treatment Patterns In Acute Heart Failure Stratified By Renal Function: A Prospective Observational Study, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78.
2. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014 Feb;35(7):455-69.
3. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007 Aug;13(6):422-30.
4. Metra M, Cotter G, Senger S, Edwards C, Cleland JG, Ponikowski P, et al. Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion: a post hoc analysis of the PROTECT data. Circ Heart Fail. 2018 Nov;11(11):e005251.
5. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008 Jan;4(1):47-57.
6. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71.
7. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Aug;20(8):1230-1239.
8. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004 Sep 1;44(5):1587-92.